跳至主要内容
临床试验/IRCT20240416061507N1
IRCT20240416061507N1尚未招募4 期

Evaluating the efficacy and safety of Deoxycholic acid injection (Embella®) in reduction of flank fat

Espad Pharmed Co0 个研究点目标入组 30 人开始时间: 待定最近更新:
适应症

试验速览

阶段
4 期
状态
尚未招募
发起方
入组人数
30

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
21 years 至 65 years(—)
性别
All

入选标准

  • Mild to moderate flank fat (clinically proven and based on caliper measurements and ultrasound criteria)
  • Ability to complete the study and follow instructions
  • Informed consent to participate in the study
  • Consent on not performing any other intervention in the flank area during the study period

排除标准

  • Severe medical or psychological conditions that interfere with the study results
  • History of hypersensitivity to components of the product under study
  • Pregnancy and breastfeeding
  • History of previous flank fat treatment
  • Patients prone to intravascular volume reduction
  • Evidence of recent alcohol or drug abuse
  • History of bleeding disorders or recent consumption (less than 3 weeks) of thrombolytic drugs, anticoagulants, platelet inhibitors orNSAIDs
  • History of hypertrophic scarring
  • Infection, inflammation, dermatosis, unhealed wound, cancer or precancerous lesions at the injection site

研究者

发起方
Espad Pharmed Co

相似试验